Psilocybin for Depression: What Will FDA Approval

Why is the FDA examining psychedelic treatments now?

The FDA convened a public hearing on September 14 to gather perspectives on the potential therapeutic use of psychedelic drug products in supervised, supportive settings. The discussion matters because evaluating these medicines involves more than determining whether symptoms improve: the conditions under which treatment is delivered also deserve scrutiny. The hearing was a consultation about potential future use, rather than a product approval announcement. [FDA hearing announcement](https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/considerations-potential-future-therapeutic-use-psychedelic-drugs-public-hearing-09142026).

One closely watched candidate is COMP360, Compass Pathways' investigational synthetic psilocybin formulation for treatment-resistant depression. In its August 5 update, the company said a rolling application submission and initial FDA review were underway, with completion of the application expected in the fourth quarter. These statements describe the developer's reported progress and plans; they do not establish an approval date or guarantee that the treatment will become available. [Compass Pathways regulatory update](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Second-Quarter-and-First-Half-2026-Financial-Results-and-Business-Highlights/default.aspx).

What do psilocybin clinical trials show about depression?

In February, Compass reported that its second pivotal phase 3 trial, COMP006, met its primary endpoint. Two administrations of 25 mg COMP360 produced a greater average reduction in depression scores at six weeks than two administrations of 1 mg, with a reported between-group difference of 3.8 points on the Montgomery–Åsberg Depression Rating Scale. Its first pivotal trial, COMP005, also met its primary endpoint. These are sponsor-reported findings: a statistically significant average difference does not mean every participant improved or achieved remission. The company also reported adverse events, including headache, nausea and anxiety, and serious adverse events requiring assessment. [Compass phase 3 results announcement](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-Second-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/).

Earlier peer-reviewed research provides additional context. A 2023 JAMA randomized trial involving 104 adults with major depressive disorder found greater improvement with a single psilocybin dose plus psychological support than with niacin plus support over six weeks. However, the study excluded people with histories of psychosis or mania and those with active suicidal intent. That limits how confidently its findings can be applied to those groups. It also studied major depressive disorder, so its population should not be treated as interchangeable with the treatment-resistant population in COMP360's pivotal program. [Raison and colleagues, JAMA](https://doi.org/10.1001/jama.2023.14530).

What evidence and safeguards matter before approval?

A distinctive research problem is functional unblinding: noticeable psychedelic effects can reveal treatment assignment to participants or staff, allowing expectations to influence symptom ratings. FDA guidance discusses independent blinded raters and alternative comparison treatments to address this problem. It also recommends evaluating treatment effects at 12 weeks for chronic conditions such as depression, with longer follow-up to assess recurrence and repeat dosing. [FDA clinical investigation guidance](https://www.fda.gov/media/169694/download?attachment=).

Safety assessment extends beyond the dosing session. Researchers must consider altered judgment, psychological vulnerability and adverse effects, alongside the durability of improvement. The FDA guidance describes observation by two monitors during treatment sessions and consideration of safeguards that could be needed after approval. These recommendations concern clinical development; the conditions attached to any future approved product would depend on its own evidence and regulatory assessment. [FDA safety considerations](https://www.fda.gov/media/169694/download?attachment=).